PANMYCIN Drug Patent Profile
✉ Email this page to a colleague
When do Panmycin patents expire, and when can generic versions of Panmycin launch?
Panmycin is a drug marketed by Pharmacia And Upjohn and is included in two NDAs.
The generic ingredient in PANMYCIN is tetracycline hydrochloride. There are ninety-nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the tetracycline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Panmycin
A generic version of PANMYCIN was approved as tetracycline hydrochloride by WATSON LABS on December 31st, 1969.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PANMYCIN?
- What are the global sales for PANMYCIN?
- What is Average Wholesale Price for PANMYCIN?
Summary for PANMYCIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 66 |
| Patent Applications: | 3,152 |
| DailyMed Link: | PANMYCIN at DailyMed |
US Patents and Regulatory Information for PANMYCIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacia And Upjohn | PANMYCIN | tetracycline hydrochloride | CAPSULE;ORAL | 060347-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pharmacia And Upjohn | PANMYCIN | tetracycline hydrochloride | TABLET;ORAL | 061705-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pharmacia And Upjohn | PANMYCIN | tetracycline hydrochloride | TABLET;ORAL | 061705-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
